RA CAPITAL MANAGEMENT, L.P.
Institutional investor · Portfolio as of Q4 2024
Top Holdings89 positions
Stock | Shares | Value | Weight | Avg Buy | Est. P&L | Held | Conviction |
|---|---|---|---|---|---|---|---|
ASCENDIS PHARMA A/S | 10.1M | $1.4B | 18.5% | $94.49 | +44.44% | 25 qtrssince 2018-Q4 | Increased 65 |
VAXCYTE INC | 8.7M | $711.3M | 9.5% | $40.85 | +100.69% | 19 qtrssince 2020-Q2 | Unchanged 0 |
JANUX THERAPEUTICS INC | 10.4M | $555M | 7.4% | $27.78 | +88.98% | 15 qtrssince 2021-Q2 | Increased 69 |
RHYTHM PHARMACEUTICALS INC | 6.1M | $340.6M | 4.5% | $25.49 | +121.06% | 25 qtrssince 2018-Q4 | Unchanged 0 |
Legend Biotech Corp. Sponsored ADR | 7.5M | $244.3M | 3.3% | $57.21 | -64.40% | 10 qtrssince 2022-Q3 | Unchanged 0 |
EDGEWISE THERAPEUTICS INC | 8.9M | $237.9M | 3.2% | $18.24 | +48.36% | 4 qtrssince 2024-Q1 | Unchanged 0 |
NewAmsterdam Pharma Company N.V. | 8.8M | $227.3M | 3.0% | $12.99 | +97.10% | 9 qtrssince 2022-Q4 | Increased 62 |
WAVE LIFE SCIENCES LTD | 18.2M | $225.2M | 3.0% | $19.79 | -37.31% | 25 qtrssince 2018-Q4 | Unchanged 0 |
ARCELLX INC | 2.8M | $213.8M | 2.8% | $65.41 | +19.78% | 3 qtrssince 2024-Q2 | Increased 73 |
| 6.3M | $183.2M | 2.4% | $13.96 | +108.99% | 14 qtrssince 2021-Q3 | Unchanged 0 | |
Septerna, Inc. | 7M | $160.2M | 2.1% | $23.23 | 0.00% | 1 qtr | New 79 |
DYNE THERAPEUTICS INC | 6.4M | $150.3M | 2.0% | $29.86 | -20.79% | 4 qtrssince 2024-Q1 | Unchanged 0 |
TYRA BIOSCIENCES INC | 10.6M | $147.9M | 2.0% | $16.70 | -16.74% | 14 qtrssince 2021-Q3 | Increased 49 |
RXSIGHT INC | 3.7M | $128.7M | 1.7% | $20.41 | +65.63% | 14 qtrssince 2021-Q3 | Decreased 0 |
BICARA THERAPEUTICS INC | 7M | $121.2M | 1.6% | $25.44 | -33.18% | 2 qtrssince 2024-Q3 | Unchanged 0 |
LENZ THERAPEUTICS INC | 4.2M | $120.6M | 1.6% | $22.33 | +34.66% | 4 qtrssince 2024-Q1 | Unchanged 0 |
ARS PHARMACEUTICALS INC | 10.9M | $114.6M | 1.5% | $5.93 | +79.17% | 9 qtrssince 2022-Q4 | Unchanged 0 |
89BIO INC | 14.2M | $110.9M | 1.5% | — | — | 21 qtrssince 2019-Q4 | Unchanged 0 |
SPDR S&P BIOTECH ETF | 1.2M | $110.6M | 1.5% | $89.56 | +75.76% | 1 qtr | New 69 |
GERON CORP | 30M | $106.2M | 1.4% | $2.12 | +60.19% | 19 qtrssince 2020-Q2 | Decreased 0 |
RA CAPITAL MANAGEMENT, L.P. manages $7.5B across 89 positions as of Q4 2024. Top holdings: ASND (18.5%), PCVX (9.5%), JANX (7.4%). Fund DNA: Balanced Allocator. HoldingsIntel Rating: 2/5.0.
Active quarter - 17 new positions, 9 exits, 9 increased. Top move: SEPN (NEW, conviction 79). Portfolio: $7.5B across 89 positions.
Top holdings by portfolio weight
Portfolio allocation by GICS sector
Behavioral investing profile
Position Outcomes
Best and worst performing positions by estimated return
Top Winners
Top Losers
Cost basis estimates based on full filing history using quarter-end prices. Actual transaction prices are not disclosed in 13F filings.
Similar Funds
Funds with similar investing DNA
Explore More
Accumulation Streaks
Positions with 2+ consecutive quarters of increases - persistent directional conviction.
Continue exploring
Data sourced from SEC EDGAR 13F filings. Not financial advice. Full disclaimer